In a landmark development for the Canadian healthcare industry, Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada’s largest pharmaceutical company, have jointly announced an exclusive out-licensing agreement. This strategic alliance is set to revolutionize the Canadian eyecare market by introducing a suite of innovative ophthalmic treatments. Under this exclusive […]
Harrow Health, an ophthalmic therapies developer, will acquire the exclusive US commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies for up to $175 million. Under the terms of the arrangement, the Nasdaq-listed Harrow will make a one-time payment of $130 million at closing and up to an additional $45 million […]
IHEEZO FDA approval : Harrow Health, a Nasdaq-listed eyecare pharmaceutical company, and Sintetica have secured approval for IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% from the US Food and Drug Administration (FDA) approval for ocular surface anesthesia. Sintetica, which is based in Switzerland, is focused on emergency and intensive care, analgesics, sterile injectable solutions, and local […]